Evidence map›Paper›PMID 37410232›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.

Youngrok Park, Alana Lelo, Brent Harris, Deborah L Berry, Krysta Chaldekas, Jung-Sik Kim, Todd Waldman

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
6.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Youngrok ParkDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Alana LeloDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Brent HarrisDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Deborah L BerryDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Krysta ChaldekasDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Jung-Sik KimDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Todd WaldmanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. waldmant@georgetown.edu.
Georgetown University Medical Center · USGeorgetown University · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
STAG2 mutations and 3D genome organization in glioblastoma multiformeR01CA267872 · NCI · GEORGETOWN UNIVERSITY · PI Fulai Jin, TODD A WALDMAN · 2022 to 2026
$2.7M
Analysis of STAG2 Inactivation and Aneuploidy in Human CancerR01CA169345 · NCI · GEORGETOWN UNIVERSITY · PI WALDMAN, TODD A · 2013 to 2017
$1.6M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA169345NCI NIH HHS R01 CA267872
6 · The paper itself

Abstract

Bladder cancer is the fifth most common cancer in the United States. Most bladder cancers are early-stage lesions confined to the mucosa or submucosa and are therefore classified as non-muscle-invasive bladder cancer (NMIBC). A minority of tumors are diagnosed after they have invaded the underlying detrusor muscle and are classified as muscle-invasive bladder cancer (MIBC). Mutational inactivation of the STAG2 tumor suppressor gene is common in bladder cancer, and we and others have recently demonstrated that STAG2 mutation status can be used as an independent prognostic biomarker to predict whether NMIBC will recur and/or progress to MIBC. Here we describe an immunohistochemistry-based assay for identifying the STAG2 mutational status of bladder tumors.

Indexed as

Antigens, NuclearUrinary Bladder NeoplasmsCell Cycle ProteinsCohesinsHumansImmunohistochemistryNeoplasm InvasivenessNeoplasm Recurrence, LocalAntigens, NuclearCell Cycle ProteinsCohesinsSTAG2 protein, humanBiomarkerBladder cancerCohesinImmunohistochemistrySTAG2

Identifiers

PMID37410232
OpenAlexW4383301614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.